Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459151 | 1.00 | SORD (0.51) | SORDALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL28145714 | 0.89 | SORD (0.45) | SORDALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL9767811 | 0.86 | — | — | |
| SCHEMBL30775404 | 0.82 | SORD (0.56) | SORDALDH1A1SMN1; SMN2GSK3BLMNA | |
| SCHEMBL4453478 | 0.82 | SORD (0.56) | SORDALDH1A1SMN1; SMN2GSK3BLMNA | |
| SCHEMBL18768480 | 0.81 | SORD (0.46) | SORDCYP1A2CYP2C9CYP2C19PIK3CA | |
| SCHEMBL209842 | 0.80 | SORD (0.54) | SORDALDH1A1CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL29611181 | 0.80 | SORD (0.54) | SORDALDH1A1CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL209844 | 0.80 | SORD (0.54) | SORDALDH1A1CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL2103794 | 0.78 | SORD (0.53) | SORDLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12194031-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2025-01-14 | — | — | US | disclosed |
| US-20240374523-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | ACADIA WOODS PARTNERS, LLC | 2024-11-14 | — | — | US | disclosed |
| WO-2024191947-A1 | PIKFYVE INHIBITOR COMBINATION THERAPY | ORPHAI THERAPEUTICS INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240277720-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | ACADIA WOODS PARTNERS, LLC | 2024-08-22 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | disclosed |
| WO-2024118515-A1 | PIKFYVE INHIBITOR COMBINATION THERAPY | ORPHAI THERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024107448-A1 | APILIMOD COMBINATION THERAPY | ORPHAI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024015281-A1 | APILIMOD COMBINATION THERAPY | AI Therapeutics, Inc. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230285375-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | AARHUS UNIVERSITET (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11666561-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2023-06-06 | — | — | US | disclosed |
| US-20230069069-A1 | COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS | AI Therapeutics, Inc. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022261499-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | AI Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100016-A1 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE | AI Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022197667-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | YOUNG PETER R (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11439649-B2 | Combination therapy with apilimod and glutamatergic agents | AI Therapeutics, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-11266654-B2 | Apilimod compositions and methods for using same | AI Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | ZAP70, PIK3R4, PIKFYVE | SORD 2580/4885ALDH1A1 4573/4885HPGD 3115/4885 |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | PIKFYVE, APAF1, API5 | SORD 3809/4885ALDH1A1 4772/4885HPGD 3680/4885 |
| US-11266654-B2 | Apilimod compositions and methods for using same | API5, HAAO, PDE3B | SORD 1281/4885ALDH1A1 400/4885HPGD 80/4885 |
| US-20240277720-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | PRNP, PARK7, API5 | SORD 126/4885ALDH1A1 3447/4885HPGD 2075/4885 |
| US-11439649-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | SORD 2508/4885ALDH1A1 1760/4885HPGD 1719/4885 |
| US-20240374523-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | PRNP, PARK7, API5 | SORD 126/4885ALDH1A1 3447/4885HPGD 2075/4885 |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | SORD 4783/4885ALDH1A1 633/4885HPGD 2318/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | SORD 4783/4885ALDH1A1 633/4885HPGD 2318/4885 |
| US-20230069069-A1 | COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS | GRIK4, GRIN3A, GRIN2A | SORD 2508/4885ALDH1A1 1760/4885HPGD 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.